Market Overview

Benzinga's Top Downgrades

Related POZN
Pozen Submits Final Study Report for PA8140/PA32540 Phase 1 Study on Schedule
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates
Related MYGN
ResMed Posts In-line Earnings but Misses on Revs - Analyst Blog
Can Varian Medical Systems (VAR) Surprise This Earnings Season? - Analyst Blog

Analysts at Ascendiant downgraded POZEN (NASDAQ: POZN) from “strong buy” to “neutral.” The target price for POZEN is set to $10. POZEN's shares closed at $9.77 on Friday.

JMP Securities downgraded Myriad Genetics (NASDAQ: MYGN) from “market perform” to “underperform.” The target price for Myriad Genetics is set to $15. Myriad Genetics' shares closed at $24.14 on Friday.

Posted-In: Top DowngradesDowngrades Analyst Ratings


Most Popular

Related Articles (MYGN + POZN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free